PTC Therapeutics Inc

19 paź 2026, 20:01 UTC

PTC Therapeutics Inc shares are advancing despite a broader market downturn, continuing the upward momentum observed in recent sessions.

15 paź 2026, 20:02 UTC

UBS analyst Joon Lee raised the price target on PTC Therapeutics Inc to $90.00 from $80.00 while maintaining a Buy rating.

13 paź 2026, 20:01 UTC

PTC Therapeutics Inc shares fell sharply, continuing a decline near the low end of their one-month range and below the 20-day moving average.

9 paź 2026, 20:01 UTC

PTC Therapeutics Inc shares are advancing, recovering from an earlier dip, as the iShares Biotechnology ETF also rises, supported by strong gains in key holdings.

8 paź 2026, 20:07 UTC

RBC Capital maintains its Sector Perform rating on PTC Therapeutics and lowers its price target to $75, contributing to the stock's decline.

6 paź 2026, 20:07 UTC

PTC Therapeutics Inc's shares are trading roughly flat, retracing from earlier gains and remaining below the 20-day moving average amid a routine biotechnology sector performance.

28 wrz 2026, 20:01 UTC

PTC Therapeutics Inc. is higher in Monday's trading session, continuing gains since Friday's close, despite an earlier pullback from a session high.

25 wrz 2026, 20:01 UTC

PTC Therapeutics Inc is advancing as the broader market gains, despite earlier pulling back from a session high amid rising Treasury yields and weak consumer sentiment.

24 wrz 2026, 20:07 UTC

PTC Therapeutics Inc. shares fell, closing below the 20-day moving average and near the lower end of its one-month range after midday fluctuations.

23 wrz 2026, 20:02 UTC

PTC Therapeutics Inc shares fell sharply amid a broader downturn in the biotechnology sector, influenced by significant losses in the Direxion Daily S&P Biotech Bull 3X ETF.

18 wrz 2026, 20:02 UTC

PTC Therapeutics Inc shares fell sharply, reversing a trend of higher daily closes seen in recent sessions, despite no specific news impacting the company.

16 wrz 2026, 19:06 UTC

PTC Therapeutics gained after Leerink Partners initiated coverage with an "outperform" rating and a $98.00 price target, while Jefferies and Citigroup upgraded their ratings.

14 wrz 2026, 20:08 UTC

Leerink has initiated coverage on PTC Therapeutics with an Outperform rating and a $98.00 price target, supporting a higher trading session since Friday's close.

11 wrz 2026, 19:56 UTC

PTC Therapeutics Inc shares are lower today amid discussions from an investor event and plans for a Biologics License Application for a Fabry disease treatment.

10 wrz 2026, 23:41 UTC

PTC Therapeutics Inc shares are higher in after-market trading, gradually increasing since Thursday's close, despite remaining below their 20-day moving average.

8 wrz 2026, 20:07 UTC

Shares lower amid decline in iShares Biotechnology ETF.

2 wrz 2026, 20:08 UTC

PTC Therapeutics Inc. is gaining today, supported by a broader advance in biotechnology stocks, despite a pullback earlier in the session.

31 sie 2026, 19:46 UTC

PTC Therapeutics shares are lower today, continuing a recent decline amid broader market unease following hawkish comments from Federal Reserve Chair Kevin Warsh.

28 sie 2026, 23:36 UTC

PTC Therapeutics Inc shares are higher in after-market hours, recovering from an earlier dip. No specific news was identified to explain the movement.

27 sie 2026, 20:07 UTC

PTC Therapeutics shares are lower today, continuing a decline since Wednesday's close, despite positive labor market data. No specific news was identified.

25 sie 2026, 20:09 UTC

PTC Therapeutics shares are higher as the company announces multiple data presentations for Sephience™ at an upcoming symposium in Helsinki.

24 sie 2026, 19:56 UTC

PTC Therapeutics shares rise as new data shows Sephience treatment significantly reduces blood phenylalanine levels in patients with phenylketonuria.

21 sie 2026, 19:26 UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid a broader market rebound in safe-haven assets.

20 sie 2026, 20:02 UTC

PTC Therapeutics shares are lower amid significant downward pressure on biotechnology stocks. The stock remains below its 20-day moving average.

19 sie 2026, 19:46 UTC

PTC Therapeutics is acquiring the ST-920 gene therapy asset for $111 million, including potential milestone payments, as shares trade higher since Tuesday's close.

18 sie 2026, 19:36 UTC

PTC Therapeutics Inc shares are lower amid cautious market sentiment influenced by rising treasury yields and inflation concerns. No specific news was identified for the decline.

14 sie 2026, 19:46 UTC

PTC Therapeutics shares are lower, reflecting broader market sentiment after U.S. retail sales unexpectedly declined in July. The stock is below its 20-day moving average.

13 sie 2026, 19:36 UTC

PTC Therapeutics announced the acquisition of ST-920 for $111 million. Shares are lower amid ongoing bearish trends, despite Wells Fargo's Overweight rating and $109 price target.

12 sie 2026, 23:51 UTC

PTC Therapeutics acquires ST-920 gene therapy for $111 million, enhancing its rare disease portfolio. Shares are higher in after-market hours.

11 sie 2026, 19:46 UTC

PTC Therapeutics Inc is trading lower amid market adjustments following last Friday's weak jobs report and ahead of upcoming U.S. inflation data releases.